NEUROENDOCRINE TUMOR TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Neuroendocrine Tumor Treatment Market - Drivers

• Increasing number of clinical trials: A rising number of clinical trials for peptide-targeted radionuclide therapy development by market players is expected to create growth opportunities for the global neuroendocrine tumor treatment market in the near future. For instance, in June 2021, Clovis Oncology, Inc., a U.S.-based pharmaceutical company, announced that the first clinical site for the Phase 1/2 LuMIERE study of FAP-2286, its novel peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein (FAP), is now open at the O’Neal Comprehensive Cancer Center at The University of Alabama at Birmingham (UAB). The Phase 1 portion of the LuMIERE study will evaluate the safety of the FAP-targeting investigational therapeutic agent and identify the recommended Phase 2 dose and schedule of lutetium-177 labeled FAP-2286 (177Lu-FAP-2286). FAP-2286 labeled with gallium-68 (68Ga-FAP-2286) will be utilized as an investigational imaging agent to identify patients with FAP-positive tumors appropriate for treatment with the therapeutic agent. Once the Phase 2 dose is determined, Phase 2 expansion cohorts are planned for multiple tumor types.
• Increasing adoption of growth strategies: Market players are focusing on inorganic growth strategies such as collaboration to expand the sales of their products, and this is expected to boost the growth of the global neuroendocrine tumor treatment market over the forecast period. For instance, in December 2021, Radiomedix, Inc., a biotechnology company, in collaboration with Orano Med LLC, the global leader in high performance chelating agent technology that offers a broad range of services and products, announced the initiation of a multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin-positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive). This is currently in Phase 2 and is expected to get completed by December 2023.

Global Neuroendocrine Tumor Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, faced problems regarding transportation of products from one place to another.

The COVID-19 pandemic also had a negative impact on the global neuroendocrine tumor treatment market. For instance, according to a article published in January 2021, titled "Impact of the COVID-19 pandemic on neuroendocrine tumor services in England" in the journal Endocrine, there were particular worries about the specialized tumor treatment services during the COVID-19 pandemic. According to the same article, the major interruption in specialist neuroendocrine treatment services included noticeably longer wait times for both new and follow-up consultations, with follow-up appointments being delayed the most.

Global Neuroendocrine Tumor Treatment Market: Restraint

• Current limitations in pancreatic cancer treatment : According to an article published in the National Center for Biotechnology Information (NCBI) on July 28, 2020, pancreatic neuroendocrine tumors (PNETs) are characterized by significant heterogeneity, which is the major challenge associated with the management of neoplasia. Also, the majority of PNET therapeutics only stabilize the disease with minimal benefits for patients. Lack of specific biomarkers inhibits the early diagnosis and selection of effective drugs in clinics. The absence of preclinical models, mainly cellular models, limits effective anticancer examination and a better understanding of the biology of PNETs in the laboratory. Immunotherapy does not work in neuroendocrine tumor patient population. Nevertheless, several molecules are emerging as new therapeutic targets for the management of PNETs.